Investment analysts at StockNews.com began coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.
Shares of NH opened at $0.54 on Wednesday. The stock has a fifty day moving average price of $0.62 and a two-hundred day moving average price of $0.79. NantHealth has a 52-week low of $0.46 and a 52-week high of $2.64. The company has a market cap of $48.52 million, a price-to-earnings ratio of -1.08 and a beta of 1.69.
NantHealth (NASDAQ:NH – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). During the same quarter in the previous year, the company posted ($0.10) earnings per share. On average, sell-side analysts forecast that NantHealth will post -0.39 EPS for the current fiscal year.
NantHealth Company Profile (Get Rating)
NantHealth, Inc, together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions.
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.